| Literature DB >> 17039236 |
B Cauwelier1, H Cavé, C Gervais, M Lessard, C Barin, C Perot, J Van den Akker, F Mugneret, C Charrin, M P Pagès, M-J Grégoire, P Jonveaux, M Lafage-Pochitaloff, M J Mozzicconacci, C Terré, I Luquet, P Cornillet-Lefebvre, B Laurence, G Plessis, C Lefebvre, D Leroux, H Antoine-Poirel, C Graux, L Mauvieux, P Heimann, C Chalas, E Clappier, B Verhasselt, Y Benoit, B D Moerloose, B Poppe, N Van Roy, K D Keersmaecker, J Cools, F Sigaux, J Soulier, A Hagemeijer, A D Paepe, N Dastugue, R Berger, F Speleman.
Abstract
Recently, we and others described a new chromosomal rearrangement, that is, inv(7)(p15q34) and t(7;7)(p15;q34) involving the T-cell receptor beta (TCRbeta) (7q34) and the HOXA gene locus (7p15) in 5% of T-cell acute lymphoblastic leukemia (T-ALL) patients leading to transcriptional activation of especially HOXA10. To further address the clinical, immunophenotypical and molecular genetic findings of this chromosomal aberration, we studied 330 additional T-ALLs. This revealed TCRbeta-HOXA rearrangements in five additional patients, which brings the total to 14 cases in 424 patients (3.3%). Real-time quantitative PCR analysis for HOXA10 gene expression was performed in 170 T-ALL patients and detected HOXA10 overexpression in 25.2% of cases including all the cases with a TCRbeta-HOXA rearrangement (8.2%). In contrast, expression of the short HOXA10 transcript, HOXA10b, was almost exclusively found in the TCRbeta-HOXA rearranged cases, suggesting a specific role for the HOXA10b short transcript in TCRbeta-HOXA-mediated oncogenesis. Other molecular and/or cytogenetic aberrations frequently found in subtypes of T-ALL (SIL-TAL1, CALM-AF10, HOX11, HOX11L2) were not detected in the TCRbeta-HOXA rearranged cases except for deletion 9p21 and NOTCH1 activating mutations, which were present in 64 and 67%, respectively. In conclusion, this study defines TCRbeta-HOXA rearranged T-ALLs as a distinct cytogenetic subgroup by clinical, immunophenotypical and molecular genetic characteristics.Entities:
Mesh:
Substances:
Year: 2006 PMID: 17039236 DOI: 10.1038/sj.leu.2404410
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528